Dendright announces first human dose of DEN-181 in Phase 1b clinical trial

BRISBANE, November 14, 2017

Dendright Pty Limited, a clinical-stage biotechnology company developing a first-in-class immunotherapy for the treatment of rheumatoid arthritis today announced it has commenced first-in-human dosing of its product candidate, DEN-181 in a Phase 1b clinical trial.

Dendright extends collaboration with Johnson & Johnson Innovation and adds Arthritis Queensland as a partner to develop rheumatoid arthritis immunotherapy

BRISBANE, January 13, 2017

Dendright Pty Ltd today announced that US-based Janssen Biotech, Inc. has agreed to provide additional funding to support further research under its R&D Collaboration and Option to License Agreement to progress Dendright’s tolerizing immunotherapy to the clinic for the treatment of patients with rheumatoid arthritis (RA).

Dendright Awarded Key Patent for Autoimmune Therapy Platform

BRISBANE, March 16, 2015

Dendright Pty Ltd, a biopharmaceutical company developing novel drugs for autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for US Patent Application 12/444,790, its core technology patent which describes the particulate co-delivery of target antigens and NF-kB inhibitors to immune cells. The issuance of this patent will underpin the commercialization of products directed at immunomodulation in order to treat or prevent undesirable immune responses associated with autoimmunity, allergy and transplantation associated diseases.

Dendright-Janssen deal receives industry awards from two different competitions

September 22, 2014

Dendright is very pleased to announce that last week it received two awards for outstanding research and commercialisation endeavours pertaining to its liposome-based therapy for rheumatoid arthritis, from industry body Knowledge Commercialisation Australia (KCA) as well as from The University of Queensland (UQ).

Revolutionary arthritis treatment nominated for KCA Best Commercial Deal 2014

September 1, 2014

Dendright’s efforts to translate research in the field of autoimmune disease has won a nomination in the Knowledge Commercialisation Australasia (KCA) Research Commercialisation Awards.  

Dendright Announces Key Strategic Hire

September 3, 2013.

Dendright Pty Ltd, a biopharmaceutical company developing novel immune tolerizing drugs for the treatment of autoimmune disease, today announced the appointment of Helen Roberts to the position of Chief Executive Officer. Ms Roberts’ appointment follows the recent announcement of Dendright’s exciting and continuing collaboration with Janssen to support the preclinical development of a highly novel product for the treatment of rheumatoid arthritis.  

Dendright Enters into Collaboration with Janssen Biotech, Inc. to Develop Rheumatoid Arthritis Immunotherapy

August 12, 2013.

Dendright Pty Ltd, an autoimmune therapy company, today announced that it has signed a R&D collaboration and option to license agreement with US-based Janssen Biotech, Inc. (Janssen) to develop and commercialise Dendright’s tolerizing immunotherapy for the treatment of rheumatoid arthritis (RA). 

Under the terms of the agreement, Dendright will receive funding to support the preclinical development of the RA immunotherapy through to Phase I clinical trials and the development of companion biomarkers. In return, Janssen will receive an option to the exclusive worldwide right to develop and commercialise Dendright’s RA therapy.  In addition to an option payment, Dendright is eligible to receive certain potential development and sales milestones as well as tiered royalties on sales.

Innovative rheumatoid arthritis therapy receives backing from Janssen

January 16, 2012. 

Dendright, announced today that it has facilitated a strategic research collaboration agreement with Janssen-Cilag Pty Ltd in Australia, one of the Janssen pharmaceutical companies, to develop a promising treatment for a devastating immunological disease that affects millions of people around the world.

Under the agreement, Dendright Pty Ltd will receive an upfront seed grant to fund pre-clinical development of its treatment for rheumatoid arthritis (RA). Dendright remains wholly owned by UniQuest. No other terms of the deal were disclosed.